Fumarylacetoacetate hydrolase (Fah)-deficient pigs and uses thereof
Described herein is the generation of Fah +/− heterozygote pigs by homologous recombination and somatic cell nuclear transfer, and a method for producing Fah −/− homozygote pigs. The Fah-deficient pigs of the disclosure can be used for a variety of research and therapeutic purposes, such as for the expansion of human hepatocytes, and as large animal models of hereditary tyrosinemia type 1, cirrhosis and hepatocellular carcinoma.
1. A genetically modified Fah-deficient pig whose genome is homozygous for a disruption in the Fah gene such that the disruption results in loss of expression of functional FAH protein, wherein the pig exhibits decreased liver function.
2. The genetically modified Fah-deficient pig of claim 1 , wherein the disruption is an insertion, a deletion or one or more point mutations in the Fah gene.
3. The genetically modified Fah-deficient pig of claim 2 , wherein the disruption is an insertion.
4. The genetically modified Fah-deficient pig of claim 3 , wherein the insertion comprises a stop codon, a selectable marker, or both.
5. The genetically modified Fah-deficient pig of claim 1 , wherein the pig comprises transplanted human hepatocytes.
6. The genetically modified Fah-deficient pig of claim 1 , wherein the pig is immunosuppressed.
7. The genetically modified Fah-deficient pig of claim 6 , wherein the immunosuppression is the result of administration of one or more immunosuppressive agents.
8. The genetically modified Fah-deficient pig of claim 7 , wherein the one or more immunosuppressive agents are selected from the group consisting of FK506, cyclosporin A, fludarabine, mycophenolate, prednisone, rapamycin and azathioprine, and combinations thereof.
9. The genetically modified Fah-deficient pig of claim 1 , wherein the pig is immunodeficient.